Lp(a) Research Study

If you have high Lp(a) levels or a history of cardiovascular disease, you may be able to participate. Our study coordinators can answer your questions, review eligibility, and help you decide if this opportunity is right for you.

Age
18 Years and older

Gender
Male & Female

Condition
Elevated Lp(a)

Location

Questions or Interested in a Trial?

This field is for validation purposes and should be left unchanged.

Enroll in Lipoprotein (a) clinical trials Near You in Florida

Lipoprotein(a), or Lp(a), is a type of cholesterol-carrying particle in the blood. High levels of Lp(a) are largely inherited and can contribute to plaque buildup in the arteries over time. This may increase the risk of conditions such as coronary artery disease, heart attack, stroke, and peripheral artery disease.

This study is evaluating whether the investigational drug can help lower cardiovascular risk in adults with elevated lipoprotein(a). Researchers will study whether treatment may reduce events such as heart attack, stroke, or other serious cardiovascular complications.

Adults with lipoprotein(a) levels of 175 nmol/L or higher may qualify if they either have established cardiovascular disease or are at risk for a first cardiovascular event. Additional criteria apply. Contact the study team for a full eligibility review.

You will first complete screening visits to determine if the study is a good fit. If eligible, you will receive scheduled injections, attend regular study visits, and complete follow-up assessments over time. Visit schedules will be explained by the study team, and coordinators can discuss flexibility options.

All clinical studies involve potential risks. Before joining, you will receive detailed information through the informed consent process, including possible side effects and study requirements. Participant safety is closely monitored throughout the study.

There is no cost for study-related care, evaluations, or procedures. Compensation for time and travel may be available for eligible participants.